Adaptam Therapeutics
Adaptam Therapeutics is a pre-clinical Spanish biotech developing first-in-class antibody-based cancer immunotherapies (ADCs and bispecific antibodies) targeting glyco-immune checkpoints on immunosuppressive myeloid cells in solid tumors, aiming to license or co-develop these assets with large pharmaceutical partners.
- Company typePrivate
- Founded2023
- HeadquartersDonostia-san Sebastián, Spain
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adaptam Therapeutics does
Adaptam Therapeutics is a privately held pre-clinical biotech company founded in 2023 as a spin-off from CIC bioGUNE, headquartered at the Gipuzkoa Science and Technology Park in Donostia-San Sebastián, Spain. The company develops first-in-class antibody-based cancer immunotherapies — Antibody-Drug Conjugates (ADCs) and bispecific antibodies — directed against novel glyco-immune checkpoints (glycan-binding proteins and Siglecs, including Siglec-15) expressed selectively on immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs) within the solid tumor microenvironment. Its scientific foundation is anchored in published structural biology (Nature Communications, 2023) and an ERC Proof of Concept grant (€150,000) for the TAM-ADaCT ADC program, with future targets spanning multiple oncology indications where existing checkpoint inhibitors fail due to myeloid-mediated immunosuppression.
Adaptam Therapeutics firmographics
Firmographics- Name
- Adaptam Therapeutics
- Legal name
- ADAPTAM THERAPEUTICS, S.L.
- Website
- https://adaptamtx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Adaptam Therapeutics is a pre-clinical Spanish biotech developing first-in-class antibody-based cancer immunotherapies (ADCs and bispecific antibodies) targeting glyco-immune checkpoints on immunosuppressive myeloid cells in solid tumors, aiming to license or co-develop these assets with large pharmaceutical partners.
- Ownership category
- akta.pro rank
Adaptam Therapeutics industry classification
Industry- Product category
- Oncology Biologics / Cancer Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Adaptam Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Donostia-san Sebastián
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Adaptam Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Licensing / Co-development: As a pre-clinical stage biotech, Adaptam has no current revenue. The company's expected path to revenue generation is through licensing its antibody-based pipeline (ADCs and bispecific antibodies) to large pharmaceutical companies, or entering co-development partnerships, upon achievement of preclinical and clinical milestones.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Adaptam Therapeutics product offering
Product offeringCore offering
Adaptam Therapeutics develops a pre-clinical pipeline of antibody-based cancer immunotherapies, comprising antibody-drug conjugates (ADCs) and bispecific antibodies, directed against novel glyco-immune checkpoints expressed on immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs) in solid tumors. The company is currently advancing these programs through preclinical development toward IND-enabling studies.
Product overview
Adaptam Therapeutics is developing a pipeline of first-in-class antibody-based cancer immunotherapies targeting the immunosuppressive myeloid tumor microenvironment. The company's core portfolio consists of two therapeutic modalities: Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies, both directed against novel glyco-immune checkpoints (glycan-binding proteins and Siglecs) expressed in immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs). These programs aim to disrupt the immunosuppressive tumor microenvironment to deliver more effective therapies for patients with solid tumors.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody-Drug Conjugates (ADCs) First-in-class antibody-drug conjugate programs delivering cytotoxic payloads selectively to immunosuppressive myeloid cells within the solid tumor microenvironment by targeting glyco-immune checkpoints (glycan-binding proteins and Siglecs, including Siglec-15) expressed on tumor-associated macrophages (TAMs). Aimed at pharmaceutical partners developing next-generation immuno-oncology therapeutics for solid tumors unresponsive to T-cell checkpoint inhibitors.
- Bispecific Antibodies Bispecific antibody programs designed to simultaneously engage immunosuppressive myeloid cells (tumor-associated macrophages) and T cells, leveraging glyco-immune checkpoint modulation to enhance anti-tumor immune responses in solid tumors. Aimed at pharmaceutical partners seeking differentiated immuno-oncology pipeline assets.
Quantifiable outcome
- €150,000 ERC Proof of Concept grant awarded to advance ADC program against tumor-associated macrophages
Companies that use Adaptam Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Adaptam Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Adaptam Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CIC bioGUNEcoreAdaptam Therapeutics is a spin-off from CIC bioGUNE (Centre for Cooperative Research in Biosciences), a biomedical research organization in Bilbao and member of the Basque Research & Technology Alliance (BRTA). CIC bioGUNE provided the foundational scientific research in glycobiology and tumor immunology from which Adaptam originated. Prof. Jesús Jiménez-Barbero serves as scientific director of CIC bioGUNE and provided expert insights during the company's ideation and operational setup.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Adaptam Therapeutics competitors and assessment
Company assessmentDirect peers
- Dragonfly Therapeutics: Pre-clinical to clinical biotech developing bispecific antibodies and cytokine-based immunotherapies for cancer. Comparable in developing multi-specific antibody approaches to engage the immune system against tumors.
- Pyxis Oncology: Pre-clinical/clinical biotech developing ADCs and immunotherapies for difficult-to-treat cancers. Comparable modality mix (ADCs + antibody therapeutics) and oncology focus.
- CatalYm: European biotech developing antibodies that neutralize immunosuppression in the tumor microenvironment, including GDF-15. Highly comparable in targeting the immunosuppressive TME with antibody-based approaches.
- Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology, including myeloid-engaging candidates. Closely comparable in modality (bispecifics) and indication focus (solid tumors).
- Bolt Biotherapeutics: Clinical-stage company developing immune-stimulating ADCs that combine tumor-targeting antibodies with immune-activating payloads. Similar ADC-based immuno-oncology approach for solid tumors.
- Palleon Pharmaceuticals: Clinical-stage biotech developing therapeutics targeting Siglecs and glycan-immune checkpoints in the tumor microenvironment. Closest direct peer to Adaptam given the shared focus on Siglec biology for cancer immunotherapy.
Emerging players
- Domain Therapeutics: French/European pre-clinical to clinical biotech developing bispecific antibodies and GPCR-targeting immuno-oncology assets. Comparable European biotech at similar stage developing novel antibody-based immuno-oncology drugs.
- Surface Oncology: Clinical-stage biotech developing immunotherapies targeting the tumor microenvironment, including myeloid-cell programs. Comparable in focusing on disrupting immunosuppressive myeloid biology in cancer.
Broad incumbents
- Macrogenics: Clinical-stage biotech with a broad pipeline of bispecific antibodies and ADCs in oncology. Operates at a more advanced stage but uses comparable antibody-engineering platforms (DART, Fc-optimization).
- Innate Pharma: European clinical-stage biotech developing antibody-based immuno-oncology therapies, including bispecific NK-cell engagers and ADC programs. Comparable antibody-based immuno-oncology pipeline with broader clinical-stage assets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Adaptam Therapeutics social profiles
Digital presenceAdaptam Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adaptam Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Adaptam Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adaptam Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adaptam Therapeutics
What does Adaptam Therapeutics do?
Adaptam Therapeutics develops a pre-clinical pipeline of antibody-based cancer immunotherapies, comprising antibody-drug conjugates (ADCs) and bispecific antibodies, directed against novel glyco-immune checkpoints expressed on immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs) in solid tumors. The company is currently advancing these programs through preclinical development toward IND-enabling studies.
Is Adaptam Therapeutics a public or private company?
Adaptam Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Adaptam Therapeutics founded?
Adaptam Therapeutics was founded in 2023. It employs 1 to 10 people.
Where is Adaptam Therapeutics based?
Adaptam Therapeutics is headquartered in Donostia-san Sebastián, Spain, in the Europe region.
How does Adaptam Therapeutics make money?
One revenue line is on record: pharmaceutical Licensing / Co-development.
Who are Adaptam Therapeutics's main competitors?
Direct peers on record are Dragonfly Therapeutics, Pyxis Oncology, CatalYm, Compass Therapeutics, Bolt Biotherapeutics and Palleon Pharmaceuticals. Emerging players are Domain Therapeutics and Surface Oncology. Broad incumbents are Macrogenics and Innate Pharma.
Does Adaptam Therapeutics have an API?
No public API is recorded for Adaptam Therapeutics.
What industry is Adaptam Therapeutics in?
Adaptam Therapeutics's product category is Oncology Biologics / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.